Tezspire Scores in Late-Stage Eosinophilic Esophagitis Trial

AstraZeneca's asthma medication Tezspire has achieved positive results in a late-stage trial for treating eosinophilic esophagitis, a chronic inflammatory condition of the esophagus. The study, conducted in collaboration with Amgen, found that Tezspire significantly reduced inflammation in the esophagus and eased symptoms such as difficulty swallowing.

The drug, which is already approved in several countries as an add-on treatment for severe asthma, works by blocking a protein called TSLP that can trigger inflammation linked to eosinophilic conditions. This mechanism of action sets Tezspire apart from other treatments for this condition, which often rely on steroids or immunosuppressants.

The study's findings are significant because they demonstrate the potential of Tezspire as a targeted treatment for eosinophilic esophagitis. The results could also have implications for patients with severe asthma who may benefit from an additional therapeutic option.